The FINANCIAL — Daiichi Sankyo Company, Limited on August 24 announced that it has obtained approval in Japan for a supplementary indication of “tachycardiac atrial fibrillation” for Artist Tablets 2.5mg, 10mg and 20mg for the treatment of hypertension, angina, and chronic heart failure.
Artist features alpha-blocking action alongside nonselective beta-blocking with vasodilation action, and based on the beta-blocking effect, a lowering of the heart rate is shown. In both Japanese and international guidelines, heart rate control therapy is recommended for atrial fibrillation patients, according to Daiichi Sankyo.
As a result of requests received from atrial fibrillation-related medical societies, Daiichi Sankyo conducted Phase 3 clinical trials in Japan and obtained supplementary approval for Artist Tablets for the aforementioned indication.
Daiichi Sankyo aims to contribute further in the field of medicine by providing a new option through this drug to patients and medical professionals involved in the treatment of atrial fibrillation, as well as by continuing to expand its product lineup.
Discussion about this post